Latest News and Press Releases
Want to stay updated on the latest news?
-
New York, June 05, 2025 (GLOBE NEWSWIRE) -- Huma Therapeutics, the global healthcare AI company, today announced the launch of Hi Scribe, a generative AI clinical documentation tool designed to...
-
Luton, Bedfordshire, United Kingdom, June 03, 2025 (GLOBE NEWSWIRE) -- Market Overview The global Diagnostic Imaging Clinical Trials Market was valued at USD 12 billion in 2024 and is projected to...
-
PharmAla makes shipment to Yale, Agrees with Multidisciplinary Association for Psychedelic Studies to publicly post Investigator's Brochure for LaNeo MDMA
-
WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
-
Columbus, OH, May 05, 2025 (GLOBE NEWSWIRE) -- LainaHealth, formerly IncludeHealth, announced today the launch of its transformative virtual care model that pairs licensed physical therapists with...
-
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans...
-
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new...
-
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
-
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused...
-
Anteris Technologies reaches clinical milestone: 100 patients treated with DurAVR® Transcatheter Heart Valve (THV)